The objective of this single-blinded randomized controlled interventional clinical trial is
to learn about the efficacy and long-term safety of etomidate compared to propofol as an
anesthesia induction agent in patients undergoing coronary artery bypass graft (CABG)
surgery. The primary aim of this study is to determine whether patients receiving etomidate
or propofol exhibit similar requirements for vasopressor or ionotropic agents during both the
intraoperative and postoperative periods.
To achieve this goal, participants who are scheduled for CABG surgery will be randomly
assigned to receive either etomidate or propofol as the principal hypnotic agent. The
researchers will then compare the effects of these two anesthesia induction agents on various
factors, including the need for hemodynamic support, hemodynamic stability, duration of
mechanical ventilation, length of stay in the intensive care unit (ICU), and overall hospital
length of stay. Additionally, they will assess whether there are disparities in mortality
rates and readmission rates within a 6-month timeframe after the surgery.
By comparing the outcomes between the two groups, the study aims to provide valuable insights
into the potential differences in vasopressor or ionotropic agent requirements between
etomidate and propofol. This information can help inform clinical decision-making and
potentially optimize anesthesia management strategies for patients undergoing CABG surgery.